Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-23 inhibitors: A multicenter retrospective review
收藏DataCite Commons2025-05-01 更新2025-05-17 收录
下载链接：
https://data.mendeley.com/datasets/rkrps2sbx6
下载链接
链接失效反馈官方服务：
资源简介：
In routine clinical practice, biologic switching is common in adult patients with plaque psoriasis. While our group previously reported overall real-world 16-week and 52-week treatment outcomes of bimekizumab, a novel interleukin (IL)-17A/IL-17F inhibitor, limited information exists on switching class from an IL-23 inhibitor (IL-23i) to bimekizumab. This subset analysis of our retrospective cohort study specifically analyzes bimekizumab use following IL-23i exposure.
提供机构：
Mendeley Data
创建时间：
2025-02-04
